Two U.S. lawmakers are questioning whether drugmaker Mylan overcharged Medicaid for its EpiPen device, reports Reuters.
Sen. Ron Wyden (D-Ore.) and Rep. Frank Pallone (D-N.J.) are calling for an investigation into the matter.
The lawmakers, in a letter to HHS Secretary Sylvia Burwell, said they want clarification on whether EpiPen was classified as a generic, "non-innovator" drug or a brand-name drug by the Medicaid program, according to the article. The article states that branded drugs, as well as generic drugs available from a single source, are required under law to pay a rebate amount of at least 23.1 percent of the average manufacturer price. For generic drugs, that requirement is 13 percent.
Mylan emailed a statement to Reuters, contending it has complied with all laws and regulations regarding Medicaid rebates, and intends to file with regulators, by next April as required under new guidelines, for EpiPen to be classified as a "non-innovator" product.
Mylan has recently faced controversy over the high price of its EpiPen device and subsequently unveiled a $300 generic version of the allergy treatment.